On June 25th, Gelunhui reported that Yifang Biotechnology (688382.SH) stated on the investor Q&A platform that in December 2023, the market launch application for Garsorasib (D-1553 tablets) was accepted by the CDE, and it was included in the priority review program in January 2024. In June 2024, the new indication for Garsorasib (D-1553 tablets) was again included in the breakthrough therapy drug program by the CDE. The application for the new drug market is currently being promoted according to plan.
益方生物(688382.SH)：目前新药上市申请正按计划推进中
Yifang Biotechnology (688382.SH): The application for new drug release is currently being pushed forward according to plan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated